The vaccines business of the sanofi-aventis Group (NYSE: SNY; EPA: SAN) – Sanofi Pasteur (8788819) - has been vetoed by an advisory committee to the USFDA for the safety and efficacy of the company’s pentavelant combination vaccine for pediatric patients.
The said pentavalent vaccine combo (5 in 1), Pentacel® (DTaP-IPV-Hib) vaccine(1) protects against diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b (Hib).
Pentacel vaccine is the first DTaP-based combination vaccine candidate for use in infants in the U.S. that includes both polio and Hib vaccine components.
The diphtheria, tetanus, and pertussis components in Pentacel vaccine are based on the formulation in DAPTACEL® -- Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine) -- which was introduced by sanofi pasteur in the U.S. in 2002.
Find more details from the press release.
(1) The true name for Pentacel® vaccine is: Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined
[Photo Credit: KCCI.com]
.jpg)
Comment Preview